News for iTeos Therapeutics, Inc. (ITOS)

On December 31, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a substantial reduction in its holdings of ITeos Therapeutics Inc (ITOS). The fir

iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

**media[509156]**

iTeos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we are bullish on ITOS stock.

**media[490609]**

**media[476517]**

On November 14, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a significant transaction involving ITeos Therapeutics Inc (ITOS). The firm adde

On November 19, 2024, Matthew Gall, Chief Financial Officer of ITeos Therapeutics Inc, purchased 5,000 shares of the company, as reported in the SEC Filing. Fol

Iteos Therapeutics stock hits 52-week low at $8.39

Iteos Therapeutics stock hits 52-week low at $8.49

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday. The Dow traded up 0.29% to 41,512.19 while the NASDAQ f...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. Shares of iTeos Therapeutics, Inc. ITOS fell sharply in t...

Shares of Exicure, Inc. XCUR rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq c...

This is our list of the best health care stocks based on the highest return over the last 30 days.

Interim Results for the financial year 2023/2024 Interim results for the six months to 31 July 2023 Six months of progress with positive proof-of-concept data...

GuruFocus Article or News written by insider and the topic is about:

GuruFocus Article or News written by insider and the topic is about:

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.